

bs-15494R**[Primary Antibody]**

Sumo2 Rabbit pAb

Bioss
ANTIBODIES

www.bioss.com.cn

sales@bioss.com.cn


techsupport@bioss.com.cn

400-901-9800


— DATASHEET —

Host: Rabbit	Isotype: IgG	Applications: IHC-P (1:100-500) IHC-F (1:100-500) IF (1:100-500) Reactivity: Human, Mouse (predicted: Rat, Rabbit, Pig, Cow) Predicted MW.: 10.9 kDa Subcellular Location: Cytoplasm ,Nucleus
Clonality: Polyclonal		
GeneID: 6612	SWISS: P55854	
Target: Sumo2		
Immunogen: KLH conjugated synthetic peptide derived from human Sumo2: 1-80/95.		
Purification: affinity purified by Protein A		
Concentration: 1mg/ml		
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.		
Background: The small ubiquitin-related modifier (SUMO) proteins, which include SUMO-1, SUMO-2 and SUMO-3, belong to the ubiquitin-like protein family. Like ubiquitin, the SUMO proteins are synthesized as precursor proteins that undergo processing before conjugation to target proteins. Also, both utilize the E1, E2, and E3 cascade enzymes for conjugation. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processing, including nuclear transport, transcriptional regulation, apoptosis and protein stability. The unconjugated SUMO-1, SUMO-2 and SUMO-3 proteins localize to the nuclear membrane, nuclear bodies and cytoplasm, respectively. SUMO-1 utilizes Ubc9 for conjugation to several target proteins, which include IκBα, MDM2, p53, PML and Ran GAP1. SUMO-2 and SUMO-3 contribute to a greater percentage of protein modification than does SUMO-1, and unlike SUMO-1, they can form polymeric chains. In addition, SUMO-3 regulates b-Amyloid generation and may be critical in the onset or progression of Alzheimer' s disease		

— VALIDATION IMAGES —



Paraformaldehyde-fixed, paraffin embedded Mouse Lung; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with Sumo2 Polyclonal Antibody, Unconjugated (bs-15494R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.



Paraformaldehyde-fixed, paraffin embedded Human Breast Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; Antibody incubation with Sumo2 Polyclonal Antibody, Unconjugated (bs-15494R) at 1:200 overnight at 4°C, followed by conjugation to the SP Kit (Rabbit, SP-0023) and DAB (C-0010) staining.

— SELECTED CITATIONS —

- **[IF=10.6]** Junfeng Liu. et al. Targeting SUMOylation with an injectable nanocomposite hydrogel to optimize radiofrequency ablation therapy for hepatocellular carcinoma. J NANOBIOTECHNOL. 2024; 22: 338 IHC ;Mouse.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

38890737